Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study

A new look at old problems: Ovarian function suppression in the real world

“…In this large population of 21,948 women, use of OFS rose steeply in the last 2 years of the study period from an average annual prevalence of <4% to 7.2% in 2015 and 11.3% in 2016. This finding is consistent with the trend reported for a similarly defined cohort from 5 large centers in Portugal, although the absolute rates were higher: an average of 15.5% in 2006‐2013 rising to 25% in 2014‐2015 14 . Potential explanations for the lower rates reported by Reeder‐Hayes et al include later adoption of OFS in the United States in a general population in comparison with specialized centers in Europe, where a higher risk population may be referred and for which OFS may have been more clearly indicated.…”

“…This finding is consistent with the trend reported for a similarly defined cohort from 5 large centers in Portugal, although the absolute rates were higher: an average of 15.5% in 2006-2013 rising to 25% in 2014-2015. 14 Potential explanations for the lower rates reported by Reeder-Hayes et al include later adoption of OFS in the United States in a general population in comparison with specialized centers in Europe, where a higher risk population may be referred and for which OFS may have been more clearly indicated. Because the SOFT/TEXT results were first published in 2014, both analyses offer only an early glimpse at OFS uptake, and future studies will be needed to determine when and where a plateau is reached.…”

Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor–Positive Breast Cancer

“…Using an insurance claims database, Reeder-Hayes et al described increasing OFS use in the US, with a mean prevalence of 11.3% in 2016. A multicenter cohort study in Portugal showed higher prevalence rates, with a mean of 15.5% in 2006 to 2013, increasing to 25% in 2014 to 2015. The combination of OFS with TAM was preferred in our cohort, although OFS with AI is becoming more common .…”

“…A multicenter cohort study in Portugal showed higher prevalence rates, with a mean of 15.5% in 2006 to 2013, increasing to 25% in 2014 to 2015. The combination of OFS with TAM was preferred in our cohort, although OFS with AI is becoming more common . Few studies have assessed clinical adherence to OFS.…”

Ovarian Function Suppression Plus Aromatase Inhibitors or Tamoxifen in Premenopausal HR-positive Breast Cancer

“…A multicenter retrospective cohort study of premenopausal women with stage I to III hormone receptor-positive breast cancer diagnosed from 2006 to 2015 showed in the real-world setting that after 2014, the number of people using OFS increased. 25% menopausal patients used OFS, of which more than 30% of patients used OFS plus an aromatase inhibitor (AI) [16]. OFS application adds benefits to TAM as a study demonstrated that when compared with using of TAM alone, the addition of OFS to TAM reduces the patient's estradiol level, and at the same time significantly reduces the patient's breast density and endometrial thickness [17].…”